Abstract
Background Antinuclear antibody (ANA) testing is used to diagnose systemic autoimmune rheumatic disease (SARD). Nuclear homogeneous patterns on ANA-HEp-2 cells can result from anti-double-stranded DNA (dsDNA), anti-nucleosome, anti-histone, anti-Scl-70, or anti-dense fine speckles 70 (DFS70) antibodies (Abs). This study aimed to find a way to discriminate DFS70 Abs from others by way of assessing neutrophil nuclear staining on anti-neutrophil cytoplasmic antibody (ANCA) testing.
Methods Nuclear staining on ANCA-neutrophils was assessed to stratify nuclear homogeneous patterns on ANA-HEp-2 cells. Enrolled subjects included (1) young individuals with a dense fine speckled pattern on ANA testing (young non-SARD group, n = 62) and patients with (2) systemic lupus erythematosus (SLE group, n = 33); (3) rheumatoid arthritis possibly with histone, nucleosome Abs, and others (RA group, n = 45); and (4) diffuse systemic sclerosis with Scl-70 Abs (diffuse SSc group, n = 1.4
Results Negative rates (95% confidence interval) of neutrophil nuclear staining were 96.8% (88.8%– 99.6%) in the young non-SARD group, 3.0% (0.1 %–15.8%) in the SLE group, 4.4% (0.5%–15.2%) in the RA group, and 42.9% (17.7%–71.1%) in the diffuse SSc group, respectively. The negative rate of the young non-SARD group was significantly higher than those of the other groups (all P < 0.05).
Conclusions This study suggests that the assessment of nuclear staining on ANCA-neutrophils can help to stratify nuclear homogeneous patterns on ANA-HEp-2 cells and thus to determine whether the ANA pattern is attributed to DFS70 Abs, which can be found in healthy individuals, especially in children.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study was done retrospectively without a clinical trial ID. The study protocol was determined to be exempt by the Institutional Review Board of our hospital (IRB file No.: KNUH 2020-01-051).
Funding Statement
no funds
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was determined to be exempt by the Institutional Review Board of Kyungpook National University Hospital (Daegu, Korea) (IRB file No.: KNUH 2020-01-051).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of Interest The author states that there are no conflicts of interest to disclose for this study.
Another case of diffuse systemic sclerosis was added to this study.
Data Availability
.
